CoreValve for High Risk and Extreme Risk Patients; The US Pivotal Trials


Eduardo de Marchena
2014-10-30

M.D., F.A.C.C., F.A.C.P., F.S.C.A.I.
Professor of Medicine & Surgery
Associate Dean for International Medicine
Director of Interventional Cardiology
University of Miami Miller School of Medicine

More articles by this author

Stroke

Rutger-Jan Nuis 2014-10-30MD, MSc, PhDDepartment of CardiologyThoraxcenter Rotterdam, Netherlands

Intervencionismo Coronario en Venas Centrales

Jorge Villegas2014-10-30Cardiólogo IntervencionistaProfesor: F.U.C.S.Jefe de Hemodinmia Hospital Universitario Clínica San Rafael

TAVI-Induced Conduction Abnormalities

Rutger-Jan Nuis 2014-10-30MD, MSc, PhDDepartment of CardiologyThoraxcenter Rotterdam, Netherlands

In Perspective: Impact of new TAVI Devices on TAVI Complications

Eberhard Grube2014-10-30MD, FACC, FSCAIUniversity Hospital, Dept of Medicine II, Bonn, GermanyStanford University, Palo Alto, California, USA 

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

Coronary Obstruction During TAVI: A New Volumetric Index to Consider

Coronary obstruction during TAVI is an uncommon but potentially catastrophic complication, particularly in valve-in-valve procedures, in anatomies with small sinuses of Valsalva, low coronary...

EARLY TAVR: Impact of Age on Outcomes of Early TAVR in Asymptomatic Patients

Asymptomatic severe aortic stenosis represents an increasingly common clinical challenge. Although current guidelines recommend intervention once symptoms develop or left ventricular dysfunction occurs, concerns...

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...